Wacker Biosolutions to focus on biotechnology

Published: 2-Mar-2010
Manufacturing Ingredients Finance Pharmaceutical

Wacker Fine Chemicals becomes Wacker Biosolutions and concentrates on biotechnology

Wacker, the German chemical company, has changed the name of its Wacker Fine Chemicals division to Wacker Biosolutions as it gives the business a biotechnology focus.

Wacker Biosolutions will concentrate on building its business in three main areas, including pharmaceuticals, alongside its existing portfolio of fine chemicals and chemical intermediates. Its biotech products include cyclodextrins, cysteine and biologics, as well as fine chemicals and PVAc solid resins.

The Munich-based firm is currently extending process development and production capacities for the manufacture of pharmaceutical proteins at Wacker Biotech in Jena, Germany.

Wacker aims to offer tailored complete solutions to customers, taking advantage of the synergies between its chemical and biotech expertise. It sees potential in providing innovative products and technologies in the budding market for bioengineered products.

"This reorganisation lays further foundations for Wacker's future success in the growing field of biotechnology," said Gerhard Schmid, senior vice president of Wacker Biosolutions.

Over the past few years, Wacker has posted high double-digit growth with biotech products such as cyclodextrins and cysteine. The group sees future global-market potential in pharmaceutical actives, food additives and agrochemicals.

See more

You may also like

Manufacturing

Abzena named a leader in Frost & Sullivan ADC CDMO radar report

Read more
Recognition highlights integrated capabilities, proprietary technology and expertise in antibody-drug conjugates

Trending Articles

  1. Lyocontract invests €50m in new freeze-drying facility with Syntegon vial line German CDMO Lyocontract has begun construction of a €50m expansion in Ilsenburg, partnering with Syntegon to install a complete vial filling and lyophilisation line for sterile freeze-dried pharmaceuticals
  2. Why weight sorting should move earlier in OSD development Phillip Ruda explains how earlier weight intelligence can improve process understanding, reduce risk and accelerate learning cycles
  3. Orphan drug sales to exceed $400bn by 2032, Evaluate report finds Despite FDA policy shifts and the rise of blockbuster obesity drugs, a new Evaluate report confirms rare disease therapies are on track to claim more than a fifth of all global prescription drug sales within a decade
  4. Piramal Pharma Solutions’ Grangemouth facility successfully delivers 1500th ADC batch With this achievement, Piramal strengthens its leadership position in delivering critical bioconjugate therapies to patients in need

Upcoming event

DCAT Week

23–26 March 2026 | Conference | New York, US See all

You may also like

Manufacturing

Abzena named a leader in Frost & Sullivan ADC CDMO radar report

Recognition highlights integrated capabilities, proprietary technology and expertise in antibody-drug conjugates
Manufacturing

LabVantage Solutions introduces LabVantage CORTEX, advancing its LIMS platform for AI-driven laboratory operations

Next-Generation Platform Extends LIMS with Agentic AI and Cloud-Native Automation to Improve Efficiency, Reduce Errors and Gain Deeper Insight from Data. Learn More from LabVantage Leadership at Pittcon 2026
Design & Build

Entries closed: what’s next for the Cleanroom Technology Awards?

With entries now closed, attention turns to the next phase of the awards programme
Manufacturing

Schütz to build automated IBC production facility at BASF's Ludwigshafen headquarters

Packaging specialist Schütz has signed an agreement with BASF to construct a highly automated intermediate bulk container manufacturing and storage facility directly adjacent to the chemical giant's main plant in Ludwigshafen, enabling round-the-clock just-in-time delivery
You need to be a subscriber to read this article.
Click here to find out more.
Manufacturing

LGM Pharma announces $9 million investment into Colorado and Texas manufacturing facilities

The investment marks the second phase of the the company's expansion, funding facility upgrades to increase capacity for suppository, semi-solid and oral solid dose and differentiating LGM in the US CDMO market, says CEO Prasad Raje, speaking exclusively to Manufacturing Chemist
You need to be a subscriber to read this article.
Click here to find out more.
Research & Development

Atrogi doses first subjects in human trial of exercise-mimicking oral therapy ATR-258

The Swedish biotech has initiated a human trial of ATR-258, a first-in-class oral β2-adrenergic receptor modulator designed to replicate the metabolic effects of exercise, including fat loss and muscle preservation, without the cardiovascular side effects associated with traditional β2-agonists
Manufacturing

SGD Pharma partners with Prince Sterilisation Services for pharmaceutical glass packaging

The pair have already launched the My Sterinity Nasal platform, a new, versatile sterile vial range within SGD Pharma's My Sterinity RTU platform, using the company's U-Save Type I vials, which are designed to support the growing segment of high-value nasal drug delivery
Subscribe now